A Mab A Case Study In Bioprocess Development -

The development of A Mab has paved the way for the production of similar therapeutic proteins. Future directions include:

At 2L scale, everything worked. At 200L, A Mab showed unexpected (from 2% to 8%). The root cause: inhomogeneous mixing led to localized high pH (>7.8) near the base addition port.

To overcome these limitations, a comprehensive optimization program was implemented, focusing on: A Mab A Case Study In Bioprocess Development

For mAb-X, the challenge was . In a small flask, oxygen diffuses easily. In a massive stainless steel tank, the cells in the center can starve for oxygen if mixing isn't perfect.

This case study demonstrates that a modern mAb process is not developed linearly. By integrating upstream media chemistry (clone #47B + metal modulation) with downstream flocculation and high-resilience Protein A capture, the team transformed a problematic, aggregate-prone mAb (initial yield <1.5 g/L recoverable) into a robust 6.1 g/L titer process with a 71% final recovery. The drug product met all Phase I release specifications for purity, potency, and safety. The development of A Mab has paved the

Moving from a 2L benchtop bioreactor to a 2,000L production scale is where physics fights biology.

: Limiting high-molecular-weight aggregates and low-molecular-weight fragments to prevent immunogenic reactions. 2. Upstream Process Development: Maximizing Titers The root cause: inhomogeneous mixing led to localized

A central pillar of the study is the development of a . This represents the multidimensional combination and interaction of input variables (e.g., pH, temperature, feed rate) that have been demonstrated to provide assurance of quality. Working within this space is not considered a change by regulators, allowing for more operational flexibility. 3. Upstream and Downstream Development in A-mAb

The outcome was a robust run, where the culture achieved a final titer of 4.5 g/L —a benchmark that makes the manufacturing economically viable.